Identification of Hodgkin and sternberg‐reed cells as a unique cell type derived from a newly‐detected small‐cell population

Abstract

In this study the antigenic profile of Hodgkin (H) and Sternberg-Reed (SR) cells from cases of Hodgkin's disease was analysed using a large panel of monoclonal and polyclonal antibodies reactive with cells of lymphoid and haemotopoietic origin. The aim of this investigation was, firstly, to throw light on the origin of H and SR cells and, secondly, to determine whether there is any evidence to support recent suggestions that H and SR cells differ antigenically between different histological categories of Hodgkin's disease. Frozen sections (from 24 cases) and paraffin sections (83 cases) were stained by immunoenzymatic methods and the results compared with those obtained from staining a wide variety of reactive and neoplastic tissue samples (including examples of tuberculosis, sarcoidosis, malignant histiocytosis, histiocytosis X, osteomyelosclerosis and non-Hodgkin's lymphoma). The results revealed that H and SR cells of all types of Hodgkin's disease consistently lack markers found on null cells, B cells, T cells, cells of monocyte/macrophage series, interdigitating reticulum cells, dendritic reticulum cells and erythropoietic and thrombopoietic cells. However, H and SR cells constantly expressed an antigen detectable with the recently produced monoclonal antibody Ki-I. The vast majority of typical and lacunar type H and SR cells contained the granulocyte-related antigens detected by monoclonal antibodies TU5, TU6, TU9 and 3C4, whereas other more or less specific granulopoietic cell markers (such as peroxidase, chloroacetate esterade, lysozyme, cationic leukocyte antigen and OKMI) were consistently absent. H and SR cells in cases of nodular paragranuloma (nodular type of Hodgkin's disease with lymphocyte predominance) were not monotypic in light chain type (as has been previously reported), but rather contained chi and lambda chains within the same cells, as do typical and lacunar type H and SR cells. Immunostaining of normal and hyperplastic lymphoid tissue with the Ki-I antibody led to the detection of a new, as yet unidentified, small-cell population of unknown origin and function, which is present between, around, and within cortical follicles. It is concluded from these findings that H and SR cells constitute a unique cell type that differs in many properties from all other known cell types. Furthermore, H and SR cells of the various histological types of Hodgkin's disease are more closely related than previously believed. It is suggested that the hitherto unknown cell population detected with the monoclonal antibody Ki-I in normal lymphoid tissue is the normal equivalent of H and SR cells.

Anaplastic Large Cell Lymphoma: The Shifting Sands of Diagnostic Hematopathology

“…Ki-1 was subsequently shown to stain the malignant cells of HD in tissue sections, as well as a smaller lymphoid cell found in the parafollicular regions of normal lymph nodes (7). It was postulated that this CD30ϩ cell might represent a precursor lymphoid cell for the malignant cells of HD.…”

Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy

“…antibody therapy ͉ Hodgkin's lymphoma ͉ soluble CD30 ͉ monoclonal antibody ͉ conformation H uman CD30 is a promising target for cancer immunotherapy, because CD30 is highly expressed in Hodgkin's disease and anaplastic large-cell lymphoma but is expressed on a small subset of normal lymphocytes (1)(2)(3). Several different immunotherapy strategies have been tried by using CD30 as the target (4)(5)(6)(7)(8)(9)(10)(11)(12).…”

“…These include 21 mAbs that we produced against the extracellular domain of CD30 and 6 isolated by others (2,13,(32)(33)(34)(35)(36)(37). We have used these to identify eight different epitopes on CD30 (13,37,38).…”

“…A total of 27 anti-CD30 mAbs were used in this study. The mAbs to the extracellular domain of human CD30 include 21 mAbs established by us (13, 37) and 6 mAbs previously produced by others (2,(32)(33)(34)(35)(36). Their characteristics are summarized in Table 1.…”

CD30 Expression vs. Serum Soluble CD30 (sCD30) Level: Role in Prognosis and Treatment of Acute Myeloid Leukaemia

“…CD30 molecule was first off distinguished in 1982 as the antigen of the monoclonal antibody Ki-1 [5,6] and appears as a 120 kDa transmembrane glycoprotein be a member of the tumor necrosis factor receptor (TNF-R) superfamily [7], frequently expressed by Hodgkin and Reed-Sternberg (H-RS) cells in Hodgkin's disease (HD) and by malignant cells of some types of non-Hodgkin's lymphomas, such as human T-lymphotropic virus type 1-positive (HTLV-1+), CD30 anaplastic large-cell lymphoma (ALCL) and adult T-cell leukemia lymphoma (ATLL) [8,9].…”